Sudden Cardiac Death After ECT

Article Information

Ole J. Thienhaus*

1Department of Psychiatry, University of Arizona College of Medicine, Tucson, Arizona, USA

*Corresponding Author: Ole J. Thienhaus, Department of Psychiatry, University of Arizona College of Medicine, Tucson, Arizona, USA

Received: 07 September 2017; Accepted: 26 September 2017; Published: 30 September 2017

Share at Facebook


Electroconvulsive therapy is known to be one of the safest methods of treating major depressive episodes. One of the rare complications attributable directly to ECT, rather than general anesthesia, concerns cardiac death in vulnerable patients. The case presented here raises the issue that routine work-up can miss warning signs of cardiac pathology in high risk patients. A history of cocaine use disorder suggests echocardiography to rule out cardiomegaly.


Electroconvulsive therapy, Echocardiography, Psychopharmacotherapies, Psychiatric, Neurologic

Electroconvulsive therapy articles Electroconvulsive therapy Research articles Electroconvulsive therapy review articles Electroconvulsive therapy PubMed articles Electroconvulsive therapy PubMed Central articles Electroconvulsive therapy 2023 articles Electroconvulsive therapy 2024 articles Electroconvulsive therapy Scopus articles Electroconvulsive therapy impact factor journals Electroconvulsive therapy Scopus journals Electroconvulsive therapy PubMed journals Electroconvulsive therapy medical journals Electroconvulsive therapy free journals Electroconvulsive therapy best journals Electroconvulsive therapy top journals Electroconvulsive therapy free medical journals Electroconvulsive therapy famous journals Electroconvulsive therapy Google Scholar indexed journals Echocardiography articles Echocardiography Research articles Echocardiography review articles Echocardiography PubMed articles Echocardiography PubMed Central articles Echocardiography 2023 articles Echocardiography 2024 articles Echocardiography Scopus articles Echocardiography impact factor journals Echocardiography Scopus journals Echocardiography PubMed journals Echocardiography medical journals Echocardiography free journals Echocardiography best journals Echocardiography top journals Echocardiography free medical journals Echocardiography famous journals Echocardiography Google Scholar indexed journals Psychopharmacotherapies articles Psychopharmacotherapies Research articles Psychopharmacotherapies review articles Psychopharmacotherapies PubMed articles Psychopharmacotherapies PubMed Central articles Psychopharmacotherapies 2023 articles Psychopharmacotherapies 2024 articles Psychopharmacotherapies Scopus articles Psychopharmacotherapies impact factor journals Psychopharmacotherapies Scopus journals Psychopharmacotherapies PubMed journals Psychopharmacotherapies medical journals Psychopharmacotherapies free journals Psychopharmacotherapies best journals Psychopharmacotherapies top journals Psychopharmacotherapies free medical journals Psychopharmacotherapies famous journals Psychopharmacotherapies Google Scholar indexed journals Psychiatric articles Psychiatric Research articles Psychiatric review articles Psychiatric PubMed articles Psychiatric PubMed Central articles Psychiatric 2023 articles Psychiatric 2024 articles Psychiatric Scopus articles Psychiatric impact factor journals Psychiatric Scopus journals Psychiatric PubMed journals Psychiatric medical journals Psychiatric free journals Psychiatric best journals Psychiatric top journals Psychiatric free medical journals Psychiatric famous journals Psychiatric Google Scholar indexed journals Neurologic articles Neurologic Research articles Neurologic review articles Neurologic PubMed articles Neurologic PubMed Central articles Neurologic 2023 articles Neurologic 2024 articles Neurologic Scopus articles Neurologic impact factor journals Neurologic Scopus journals Neurologic PubMed journals Neurologic medical journals Neurologic free journals Neurologic best journals Neurologic top journals Neurologic free medical journals Neurologic famous journals Neurologic Google Scholar indexed journals mood disorders articles mood disorders Research articles mood disorders review articles mood disorders PubMed articles mood disorders PubMed Central articles mood disorders 2023 articles mood disorders 2024 articles mood disorders Scopus articles mood disorders impact factor journals mood disorders Scopus journals mood disorders PubMed journals mood disorders medical journals mood disorders free journals mood disorders best journals mood disorders top journals mood disorders free medical journals mood disorders famous journals mood disorders Google Scholar indexed journals vulnerable patients articles vulnerable patients Research articles vulnerable patients review articles vulnerable patients PubMed articles vulnerable patients PubMed Central articles vulnerable patients 2023 articles vulnerable patients 2024 articles vulnerable patients Scopus articles vulnerable patients impact factor journals vulnerable patients Scopus journals vulnerable patients PubMed journals vulnerable patients medical journals vulnerable patients free journals vulnerable patients best journals vulnerable patients top journals vulnerable patients free medical journals vulnerable patients famous journals vulnerable patients Google Scholar indexed journals hydrocephalus articles hydrocephalus Research articles hydrocephalus review articles hydrocephalus PubMed articles hydrocephalus PubMed Central articles hydrocephalus 2023 articles hydrocephalus 2024 articles hydrocephalus Scopus articles hydrocephalus impact factor journals hydrocephalus Scopus journals hydrocephalus PubMed journals hydrocephalus medical journals hydrocephalus free journals hydrocephalus best journals hydrocephalus top journals hydrocephalus free medical journals hydrocephalus famous journals hydrocephalus Google Scholar indexed journals intracranial pathology articles intracranial pathology Research articles intracranial pathology review articles intracranial pathology PubMed articles intracranial pathology PubMed Central articles intracranial pathology 2023 articles intracranial pathology 2024 articles intracranial pathology Scopus articles intracranial pathology impact factor journals intracranial pathology Scopus journals intracranial pathology PubMed journals intracranial pathology medical journals intracranial pathology free journals intracranial pathology best journals intracranial pathology top journals intracranial pathology free medical journals intracranial pathology famous journals intracranial pathology Google Scholar indexed journals electrolyte abnormalities articles electrolyte abnormalities Research articles electrolyte abnormalities review articles electrolyte abnormalities PubMed articles electrolyte abnormalities PubMed Central articles electrolyte abnormalities 2023 articles electrolyte abnormalities 2024 articles electrolyte abnormalities Scopus articles electrolyte abnormalities impact factor journals electrolyte abnormalities Scopus journals electrolyte abnormalities PubMed journals electrolyte abnormalities medical journals electrolyte abnormalities free journals electrolyte abnormalities best journals electrolyte abnormalities top journals electrolyte abnormalities free medical journals electrolyte abnormalities famous journals electrolyte abnormalities Google Scholar indexed journals

Article Details

1. Introduction

Electroconvulsive therapy (ECT) has established itself as a safe and effective treatment option after its use declined temporarily with the introduction of various psychopharmacotherapies for mood disorders [1]. Overall mortality of patients who receive ECT has been reported to be 0.03 percent [2].

Appropriate psychiatric and neurologic indications have been identified [3]. Techniques have been standardized and there is a fair amount of evidence for its effectiveness in inducing remission of major mood disorders. Concerns about adverse effects have mostly focused on the possibility of cognitive deterioration [4]. The actual safety of the procedure has always been seen as a tremendous asset, making ECT an excellent choice in certain higher risk patients such as patients with hydrocephalus or pregnant women who may not be good candidates for antidepressant or mood-stabilizing pharmacotherapy. Much of the low mortality associated with ECT is due to complications related to the anesthesia rather than to the procedure itself. Careful attention to preexisting cardiac conditions, electrolyte abnormalities and intracranial pathology has been crucial in making ECT so safe.

2. Case Report

In this case report, we want to present a case of a 35 year old man who died of asystole following a maintenance ECT procedure.

The patient had a well-established diagnosis of bipolar disorder, the most recent episode having been depressed. He came from a broken home, essentially being on his own as of age six, getting involved in substance use as a preteen. He used alcohol, opiates and stimulants extensively until about two years prior to his course of ECT. He continued using marijuana regularly. He was proud of his physical stamina and reported that he regularly cut down trees and chopped wood.

He had been in outpatient treatment for his bipolar disorder and tried on a variety of medications including aripiprazol, quetiapine, olanzapine, risperidone, divalproex, carbamazepine, lithium and lamotrigine. None of these medications induced sustained mood stabilization. The patient had a number of brief inpatient stays, the most recent one about a year prior to his ECT. The exact number of hospitalizations is unclear. He had had a record of short-lived employment and was eventually placed on supplemental security income.

The patient was referred for ECT by his primary psychiatrist because his mood disorder had proved refractory to other interventions. He was evaluated and found to meet diagnostic criteria for a major depressive episode as part of a bipolar disorder. At the time of ECT, the patient was maintained on olanzapine, 20 mg per day for mood stabilization, and trazodone 100 mg for sleep induction.

With a body mass index of 36.1 kg/m², he was obese and he had a history of hypertension. Otherwise, his physical examination was unremarkable. His pre-ECT work-up included all recommended studies i.e. chest film, EKG, urinalysis, complete blood count, blood glucose and urea nitrogen and serum electrolytes. All results were within normal limits. The patient was classified as ASA II because of his smoking (2 packs per day) and his obesity, but he was seen as a safe candidate for general anesthesia and ECT.

ECTs were initiated on an outpatient basis at a frequency of two procedures per week. For each treatment, the patient was prepared by administering 250 mg of caffeine to lower the seizure threshold, followed by 20 mg of etomidate and 120 mg of succinylcholine. The equipment used was a Thymatron machine. In line with the manufacturer’s recommendation, the power output was set at 20% of maximum. The patient generally had well defined, generalized attenuated tonic-clonic muscle phenomena indicating seizure lasting for 15 to 50 seconds. In the course of 13 biweekly ECTs, his postictal recovery had been uneventful each time, and the patient had reported improvement in his depressed mood. The plan was, after the 14th treatment, to reduce frequency to a twice a month schedule.

On the day of the 14th treatment, the patient was prepared the same way as on all previous occasions. His EKG, vital signs and serum electrolytes were all within normal limits. After administration of the bitemporal stimulus, the patient had a 15 second clinically visible response. After the treatment, he appeared to stabilize but then developed progressive bradycardia and, despite repeated doses of atropine and epinephrine the bradycardia ended up in asystole. External resuscitation was attempted, but after 45 minutes the patient was pronounced dead.

The patient came to autopsy. His toxicology revealed ephedrine (1,100 ng/ml) and, unsurprisingly, cannabis metabolites (?-9-tetrahydrocannabinol and ?-9-carboxy tetrahydrocannabinol at concentrations of 1.7 and 28.0 ng/ml respectively), but was otherwise negative. The cannabis metabolites were consistent with the known use of marijuana. The ephedrine concentration far exceeded that seen after therapeutic use of standard ephedrine-containing decongestants (up to 100 ng/ml) and suggests excessive use of such compounds as a substitute of his abandoned methamphetamine and cocaine abuse.

He was found to have cardiomegaly with his heart weighing 570 grams (average weight of a male heart is 300 grams), and hypertrophy of his left ventricle.

The heart is definitely coming under stress while ECT is administered. Cardiac workload initially increases with the onset of the seizure due to sympathetic stimulation originating in the diencephalon [5]. As the seizure progresses, circulating catecholamine levels rise [6]. After the seizure terminates, parasympathetic rebound commences and results in the commonly observed postictal bradycardia. It takes 5 to 10 minutes from the onset of seizure activity until the cardiac situation returns to its pre-existing equilibrium [7].

Neither the cannabinols nor the ephedrine were seen as plausible causes of the terminal asystole in this case. However, the cardiomegaly was.

The routine pre-ECT work-up failed to alert either the psychiatrist or the anesthesiologist to the patient’s cardiac condition. Neither a reported history of hypertension nor the obvious obesity were seen as reasons to initiate a more invasive cardiac assessment such as an echocardiogram or an MRI.

The use of an over-the-counter stimulant like ephedrine has been reported, in one case report, to be associated with cardiomyopathy [8], but in the present case, its use followed an extensive history of daily use of methamphetamine and cocaine. Combined, the end result of substantial cardiomegaly appears plausible. This in turn would explain increased vulnerability to the autonomic influence of the extrinsic and intrinsic sympathetic and parasympathetic agents associated with general anesthesia and ECT, and ultimately the refractory, fatally progressive bradycardia.
We submit that in patients with a history of substantial and extended abuse of stimulant drugs, the pre-ECT evaluation should include a more thorough cardiac examination than is currently routine. Volumetric measures such as an echocardiogram may well need to be integrated as a standard intervention.


  1. McDonald WM, Thompson TR, McCall WV, et al. Electroconvulsive therapy. In Schatzberg AF and Nemeroff CB (eds) Textbook of psychopharmacology. (3rd Edn). Washington DC: American Psychiatric Publishing (2004): 685.
  2. Kramer B. Use of ECT in California 1977-1983. Am J Psychiatry 142 (1985):1190-1192.
  3. American Psychiatric Association Task Force on Electroconvulsive Therapy. The practice of electroconvulsive therapy: Recommendations for treatment, training and privileging. Task Force Report on ECT. Washington DC: American Psychiatric Association (2001).
  4. Sackeim HA. Memory and ECT: From polarization to reconciliation, JECT 16 (2000): 87-96.
  5. Welch CA and Drop LJ. Cardiovascular effects of ECT. Convuls Ther 5 (1989): 35-43.
  6. Khan A, Nies A, Johnson G, et al. Plasma catecholamines and ECT. Biol Psychiatry 20 (1985): 799-804.
  7. Welch CA: Electroconvulsive therapy. In Stern TA, Rosenbaum JF, et al. Massachusetts General Hospital comprehensive clinical psychiatry. Philadelphia: Mosby Elsevier (2008): 638.
  8. To LB, Sangster JF, Rampling D, et al. Ephedrine-induced cardiomyopathy. Med J Aust 12 (1980): 35-36.

© 2016-2024, Copyrights Fortune Journals. All Rights Reserved